Ukraine is keen to secure doses of Covaxin for their country from Bharat Biotech, the Hyderabad based major said. A three-member high power delegation led by the country's health minister visited the Bharat Biotech's facility on Wednesday.
The Central Asian nation with a population of 41 million people is keen to secure doses of Covaxin, the indigenously developed Covid-19 vaccine which is yet to come out with phase 3 efficacy data, from Bharat Biotech, the firm said.
"Igor Ivashchenko, Deputy Minister of Health, Ukraine, and Ivan Konovalov, Head of Trade and Economic Department, Embassy of Ukraine in India, had a discussion with Bharat Biotech’s leadership to secure the supplies of Covaxin to Ukraine," Bharat Biotech said here. The delegation was led by the country's health minister Maksym Stepanov.
Krishna Ella, Chairman & Managing Director, Bharat Biotech International Limited, said, “We discussed potential timelines for the supply of Covaxin to Ukraine on a priority and the prospects of a partnership for our BBV 154 intranasal vaccine.”
Stepanov said that they will soon firm up the Covaxin delivery plan for mass vaccination of Ukrainian citizens and also further strengthen their partnership on the intra-nasal vaccine supplies after the initial results from its phase 1 trials.
Ella has said that they will soon have capacities to produce 40 mn doses per month. They have commissioned two facilities and the third one is in line.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU